Nath Bio-Genes (I) Ltd
NATHBIOGENNath Bio-Genes (I) Ltd
NATHBIOGENPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
8.20 | 0.58 | 1.15% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
48.68 | 9.86 | 1.47% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Nath Bio-Genes (India) is engaged in hybrid seed business and production, processing and marketing of hybrid and genetically modified (GM) seeds
Investor Presentation
View olderPeers
Compare with peersGodrej Agrovet Ltd
Gujarat Ambuja Exports Ltd
AVT Natural Products Ltd
Sukhjit Starch and Chemicals Ltd
GRM Overseas Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 185.98 | 162.80 | 170.39 | 192.59 | 233.20 | 281.71 | 309.23 | 280.21 | 301.91 | 337.54 | ||||||||||
Raw Materials | 3.59 | 4.36 | 1.97 | 2.71 | 5.49 | 7.35 | 8.96 | 3.56 | 5.31 | 282.87 | ||||||||||
Power & Fuel Cost | 0.68 | 0.52 | 0.58 | 0.73 | 0.95 | 1.02 | 1.23 | 1.07 | 1.39 | |||||||||||
Employee Cost | 15.68 | 13.63 | 13.74 | 11.89 | 16.43 | 18.74 | 23.69 | 24.78 | 23.32 | |||||||||||
Selling & Administrative Expenses | 75.79 | 68.47 | 52.09 | 48.23 | 60.86 | 75.67 | 74.85 | 89.99 | 112.25 | |||||||||||
Operating & Other expenses | 54.86 | 50.49 | 72.49 | 87.63 | 103.83 | 122.32 | 132.07 | 210.53 | 110.26 | |||||||||||
EBITDA | 35.38 | 25.33 | 29.52 | 41.40 | 45.64 | 56.61 | 68.43 | -49.72 | 49.38 | 54.67 | ||||||||||
Depreciation/Amortization | 4.39 | 3.90 | 3.03 | 0.95 | 1.45 | 1.45 | 2.82 | 3.08 | 3.01 | 3.27 | ||||||||||
PBIT | 30.99 | 21.43 | 26.49 | 40.45 | 44.19 | 55.16 | 65.61 | -52.80 | 46.37 | 51.40 | ||||||||||
Interest & Other Items | 4.66 | 6.35 | 9.73 | 10.39 | 5.33 | 6.65 | 8.87 | 10.64 | 10.21 | 9.57 | ||||||||||
PBT | 26.33 | 15.08 | 16.76 | 30.06 | 38.86 | 48.51 | 56.74 | -63.44 | 36.16 | 41.83 | ||||||||||
Taxes & Other Items | 0.94 | 0.91 | 0.47 | 0.63 | 0.44 | -1.98 | 1.09 | 3.95 | 1.13 | 1.51 | ||||||||||
Net Income | 25.39 | 14.17 | 16.29 | 29.43 | 38.42 | 50.49 | 55.65 | -67.39 | 35.03 | 40.32 | ||||||||||
EPS | 15.86 | 8.85 | 10.18 | 16.81 | 20.22 | 26.57 | 29.28 | -35.46 | 18.43 | 21.22 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | — | 0.11 | 0.09 |
Company Updates
Peers & Comparison
Consumer StaplesAgro Products
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Nath Bio-Genes (I) Ltd | 9.44 | 0.58 | 1.15% |
Godrej Agrovet Ltd | 31.00 | 3.41 | 1.95% |
Gujarat Ambuja Exports Ltd | 22.21 | 3.01 | — |
AVT Natural Products Ltd | 16.52 | 2.97 | 1.19% |
Price Comparison
Compare NATHBIOGEN with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Nath Bio-Genes (I) Ltd
Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Aditya Birla Sun Life Pure Value Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 5.0205% | Percentage of the fund’s portfolio invested in the stock 0.29% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/84 (+15) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 4, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Jul 4, 2023
Cash Dividend
Ex DateEx DateJun 23, 2022
Dividend/Share
₹2.00
Ex DateEx Date
Jun 23, 2022
Cash Dividend
Ex DateEx DateAug 18, 2021
Dividend/Share
₹2.00
Ex DateEx Date
Aug 18, 2021
News & Opinions
Dividend paying stocks 2022: 5 stocks to turn ex-dividend tomorrow
1 year ago•Livemint
Nath Bio-Genes (India) standalone net profit declines 59.14% in the September 2021 quarter
2 years ago•Business Standard
Minda Corporation Ltd leads gainers in ‘A’ group
2 years ago•Business Standard
Top stocks in focus: Aarey Drugs & Pharmaceuticals, Fortis Malar Hospitals, Nath Bio-Genes, Pricol, Gujarat Alkalies and Chemicals
2 years ago•India Infoline
Nath Bio-Genes (India) standalone net profit rises 8.85% in the June 2021 quarter
2 years ago•Business Standard
Nath Bio-Genes Standalone June 2021 Net Sales At Rs 214.64 Crore, Up 11.07% Y-o-Y
2 years ago•Moneycontrol
Take Solutions Ltd leads losers in ‘A’ group
2 years ago•Business Standard
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.41%, vs industry avg of 10.49%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.02% to 0.91%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 3.55%, vs industry avg of 7.1%